PMC:7205724 / 23923-26102 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T26","span":{"begin":1670,"end":1674},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T184","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"T185","span":{"begin":464,"end":472},"obj":"Disease"},{"id":"T186","span":{"begin":513,"end":520},"obj":"Disease"},{"id":"T187","span":{"begin":605,"end":614},"obj":"Disease"},{"id":"T188","span":{"begin":922,"end":926},"obj":"Disease"},{"id":"T189","span":{"begin":1233,"end":1237},"obj":"Disease"},{"id":"T190","span":{"begin":1403,"end":1411},"obj":"Disease"},{"id":"T191","span":{"begin":2013,"end":2021},"obj":"Disease"},{"id":"T192","span":{"begin":2135,"end":2154},"obj":"Disease"}],"attributes":[{"id":"A184","pred":"mondo_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A185","pred":"mondo_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0004656"},{"id":"A187","pred":"mondo_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A188","pred":"mondo_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A191","pred":"mondo_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

LitCovid-sample-MedDRA

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T24","span":{"begin":92,"end":104},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T25","span":{"begin":1647,"end":1664},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T26","span":{"begin":1871,"end":1887},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T27","span":{"begin":1889,"end":1903},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A24","pred":"meddra_id","subj":"T24","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062026"},{"id":"A25","pred":"meddra_id","subj":"T25","obj":"http://purl.bioontology.org/ontology/MEDDRA/10033316"},{"id":"A26","pred":"meddra_id","subj":"T26","obj":"http://purl.bioontology.org/ontology/MEDDRA/10025251"},{"id":"A27","pred":"meddra_id","subj":"T27","obj":"http://purl.bioontology.org/ontology/MEDDRA/10027876"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-PD-IDO

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T107","span":{"begin":219,"end":230},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T108","span":{"begin":327,"end":338},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T109","span":{"begin":400,"end":411},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T110","span":{"begin":506,"end":511},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T111","span":{"begin":521,"end":526},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T112","span":{"begin":555,"end":566},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T113","span":{"begin":590,"end":597},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T114","span":{"begin":641,"end":646},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T115","span":{"begin":1009,"end":1020},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T116","span":{"begin":1156,"end":1161},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T117","span":{"begin":1172,"end":1177},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T118","span":{"begin":1256,"end":1260},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T119","span":{"begin":1333,"end":1337},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T120","span":{"begin":1616,"end":1624},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"},{"id":"T121","span":{"begin":2073,"end":2087},"obj":"http://purl.obolibrary.org/obo/OGMS_0000063"},{"id":"T122","span":{"begin":2073,"end":2080},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-CHEBI

LitCovid-sample-PD-NCBITaxon

LitCovid-sample-sentences

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T196","span":{"begin":0,"end":15},"obj":"Sentence"},{"id":"T197","span":{"begin":16,"end":76},"obj":"Sentence"},{"id":"T198","span":{"begin":77,"end":247},"obj":"Sentence"},{"id":"T199","span":{"begin":248,"end":339},"obj":"Sentence"},{"id":"T200","span":{"begin":340,"end":647},"obj":"Sentence"},{"id":"T201","span":{"begin":648,"end":746},"obj":"Sentence"},{"id":"T202","span":{"begin":747,"end":847},"obj":"Sentence"},{"id":"T203","span":{"begin":848,"end":913},"obj":"Sentence"},{"id":"T204","span":{"begin":914,"end":1041},"obj":"Sentence"},{"id":"T205","span":{"begin":1042,"end":1199},"obj":"Sentence"},{"id":"T206","span":{"begin":1200,"end":1354},"obj":"Sentence"},{"id":"T207","span":{"begin":1355,"end":1559},"obj":"Sentence"},{"id":"T208","span":{"begin":1560,"end":1706},"obj":"Sentence"},{"id":"T209","span":{"begin":1707,"end":1789},"obj":"Sentence"},{"id":"T210","span":{"begin":1790,"end":1974},"obj":"Sentence"},{"id":"T211","span":{"begin":1975,"end":2088},"obj":"Sentence"},{"id":"T212","span":{"begin":2089,"end":2179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-PD-UBERON

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T26","span":{"begin":1670,"end":1674},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-Pubtator

LitCovid-sample-UniProt

LitCovid-sample-Enju

LitCovid-sample-PD-MAT

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T9","span":{"begin":1670,"end":1674},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-PD-GO-BP-0

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T37","span":{"begin":310,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T38","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T39","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T40","span":{"begin":380,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T41","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T42","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T43","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T44","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T45","span":{"begin":995,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T46","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T47","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T48","span":{"begin":1763,"end":1768},"obj":"http://purl.obolibrary.org/obo/GO_0016265"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-PD-FMA

LitCovid-sample-PD-MONDO

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T174","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"T175","span":{"begin":464,"end":472},"obj":"Disease"},{"id":"T176","span":{"begin":513,"end":520},"obj":"Disease"},{"id":"T177","span":{"begin":605,"end":614},"obj":"Disease"},{"id":"T178","span":{"begin":922,"end":931},"obj":"Disease"},{"id":"T179","span":{"begin":1233,"end":1242},"obj":"Disease"},{"id":"T180","span":{"begin":1403,"end":1411},"obj":"Disease"},{"id":"T181","span":{"begin":2013,"end":2021},"obj":"Disease"},{"id":"T182","span":{"begin":2135,"end":2154},"obj":"Disease"}],"attributes":[{"id":"A181","pred":"mondo_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A179","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A180","pred":"mondo_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0004656"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A182","pred":"mondo_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-PD-HP

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T15","span":{"begin":1626,"end":1631},"obj":"Phenotype"},{"id":"T16","span":{"begin":2135,"end":2154},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sample-GO-BP

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T33","span":{"begin":310,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T34","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T35","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T36","span":{"begin":380,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T37","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T38","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T39","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T40","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T41","span":{"begin":995,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T42","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T43","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T33","span":{"begin":310,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T34","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T35","span":{"begin":321,"end":338},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T36","span":{"begin":380,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T37","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T38","span":{"begin":394,"end":411},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T39","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T40","span":{"begin":549,"end":566},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T41","span":{"begin":995,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T42","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T43","span":{"begin":1003,"end":1020},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T196","span":{"begin":0,"end":15},"obj":"Sentence"},{"id":"T197","span":{"begin":16,"end":76},"obj":"Sentence"},{"id":"T198","span":{"begin":77,"end":247},"obj":"Sentence"},{"id":"T199","span":{"begin":248,"end":339},"obj":"Sentence"},{"id":"T200","span":{"begin":340,"end":647},"obj":"Sentence"},{"id":"T201","span":{"begin":648,"end":746},"obj":"Sentence"},{"id":"T202","span":{"begin":747,"end":847},"obj":"Sentence"},{"id":"T203","span":{"begin":848,"end":913},"obj":"Sentence"},{"id":"T204","span":{"begin":914,"end":1041},"obj":"Sentence"},{"id":"T205","span":{"begin":1042,"end":1199},"obj":"Sentence"},{"id":"T206","span":{"begin":1200,"end":1354},"obj":"Sentence"},{"id":"T207","span":{"begin":1355,"end":1559},"obj":"Sentence"},{"id":"T208","span":{"begin":1560,"end":1706},"obj":"Sentence"},{"id":"T209","span":{"begin":1707,"end":1789},"obj":"Sentence"},{"id":"T210","span":{"begin":1790,"end":1974},"obj":"Sentence"},{"id":"T211","span":{"begin":1975,"end":2088},"obj":"Sentence"},{"id":"T212","span":{"begin":2089,"end":2179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":1626,"end":1631},"obj":"Phenotype"},{"id":"T17","span":{"begin":2135,"end":2154},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"7.2 Rationale: Corticosteroids might help accelerate recovery from COVID-19\nThe study [30] investigated the effect of inhaled corticosteroids ciclesonide, cortisone, prednisolone, dexamethasone, and fluticasone on the replication of the MERS-CoV. Among the four compounds, the only ciclesonide was capable of inhibiting viral replication. Also, ciclesonide induced a significant inhibition of viral replication of other human coronaviruses, such as HCoV-229E and SARS-CoV, and another positive-strand RNA virus, rubella virus, while not affect the viral replication of negative-strand RNA viruses, e.g., influenza and respiratory syncytial virus. For the MERS-CoV, a nonstructural protein 15 (NSP15) appeared to act as the target of ciclesonide. An amino acid substitution in the NSP15 conferred resistance of the mutated MERS-CoV to ciclesonide. Mometasone could help deal effectively with the mutated MERS-CoV. For the SARS-CoV2, all three ciclesonide, mometasone, and lopinavir were able to inhibit viral replication to a similar degree. Interestingly, their effect was more noticeable than serine protease inhibitors, e.g., nafamostat and camostat in cells that Vero cells that express TMPRSS2. It indicates the tendency of the SARS-CoV2 to enter the cell through the cathepsin/endosomal pathway rather than through the TMPRSS2/cell surface pathway.\nThe study [31] included 46 patients with severe COVID-19, of these 26 patients received methylprednisolone (1–2 mg/kg/d for 5–7 days), and 20 patients received standard therapy without methylprednisolone. The first group achieved faster improvement in clinical symptoms (fever and peripheral oxygen saturation) and lung lesions detected by CT imaging. However, two deaths occurred in the first group and one death in the second group. Moreover, the two groups did not differ in laboratory parameters, including WBC, lymphocyte count, monocyte count, and cytokines (IL-2, IL-4, IL-6, and IL-10) six days after treatment.\nThere is a report of the patient with COVID-19 treated with methylprednisolone since day 8 of the disease course. However, his situation worsened and developed respiratory failure and died on day 14 [32]."}

PMC:7205724 / 23923-26102 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7205724 / 23923-26102 JSON TXT